Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Aslan and Bukwang Form JV to Develop Aslan's IO Assets

publication date: Sep 30, 2019

Singapore's Aslan Pharma formed a JV with Bukwang Pharma (KRX: 003000) of Korea to develop preclinical aryl hydrocarbon receptor (AhR) antagonists from Aslan’s early stage pipeline. The JV, Jaguahr Therapeutics, will focus on new immuno-oncology therapeutics for global markets that target the AhR pathway. Aslan will transfer global rights to all of its AhR assets into Jaguahr. Bukwang will invest $5 million in Jaguahr to fund development of the assets, identify a lead compound and file an IND application. The JV will be based in Singapore. More details....

Stock Symbol: (NSDQ: ASLN, TPEx: 6497)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here